e-Pharmatimes

Detailed Analysis: Dr. Reddy’s vs. Novo Nordisk - The Semaglutide Verdict Judgment Day: The Semaglutide Verdict Dr. Reddy’s Laboratories Ltd. vs. Novo Nordisk A/S Case Snapshot Case Number CS(COMM) 565/2025 Court Delhi High Court Judge Justice Manmeet Pritam Singh Arora Date of Decision December 2, 2025 Subject Patent Infringement (Semaglutide) Introduction In a high-stakes legal battle that has captivated the pharmaceutical industry, the Delhi H...

Litigation Update: Dr. Reddy's vs. Novo Nordisk (Semaglutide) Litigation Update • December 12, 2025 Delhi High Court Clears Dr. Reddy's for Semaglutide Exports: Refuses Novo Nordisk Stay In a significant development for the Indian pharmaceutical sector, the Delhi High Court (Division Bench) has today refused to stay a Single Judge's order permitting Dr. Reddy’s Laboratories (DRL) to manufacture and export Semaglutide. This ruling comes as a setback for Danish pharma giant Novo Nordisk , the patent holder of the blockbuster drugs Ozempic and Wegovy , which had sought to completely block DRL from manufacturing the drug in India. ⚖️ The Verdict at a Glance The Decision: The Division Bench (Justices C. Hari Shankar & O.P. Shukla) upheld the Single Judge's interim order. The Winner (Today): Dr. Reddy’s Laborator...

Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025) The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries . 🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound. 1. The Core Dispute At the heart of this litigation is Indian Patent No. 262697 . Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active p...

Delhi High Court Ruling: Novo Nordisk vs Sun Pharma on Semaglutide Litigation Update: Novo Nordisk vs Sun Pharma on Semaglutide The Delhi High Court has passed a crucial order in the ongoing patent battle between Danish pharmaceutical giant Novo Nordisk and Indian major Sun Pharma regarding the manufacture and sale of Semaglutide . Key Takeaways from the Order Export Allowed: Sun Pharma has been permitted to manufacture and export Semaglutide to countries where Novo Nordisk does not hold a valid patent. Domestic Sales Barred: The court has restrained Sun Pharma from selling the drug in the Indian market until the expiry of Novo Nordisk's specific patent in March 2026. Undertaking Recorded: Justice Manmeet Pritam Singh Arora recorded Sun Pharma's undertaking that it would not commercialize the product in India during the patent term. Background of the Dispute ...

Novo Nordisk Files FDA Application for CagriSema: A New Era in Weight Management Published: December 19, 2025 In a major move to solidify its leadership in the obesity market, Novo Nordisk officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on December 18, 2025 , for CagriSema . CagriSema is a once-weekly injectable fixed-dose combination of two powerful medications: Semaglutide (2.4 mg): The GLP-1 receptor agonist found in Wegovy. Cagrilintide (2.4 mg): A novel long-acting amylin analogue. Key Highlights from the FDA Submission The application is primarily backed by the REDEFINE 1 clinical trial, which involved over 3,400 adults. The results demonstrated superior weight loss compared to using either component alone: Treatment Group Avg. Weight Loss (68 Weeks) CagriSema 22.7% — 23% ...

Wegovy® (semaglutide 2.4 mg) Shows Liver Health Benefits in MASH Beyond Weight Loss Wegovy® (semaglutide 2.4 mg) Associated with Liver Health Benefits in MASH — Not Entirely Explained by Weight Loss Published: November 2025 | Category: Pharma & Hepatology Executive summary: A new post hoc analysis of the ESSENCE phase 3 program indicates that weekly semaglutide 2.4 mg (Wegovy®) was associated with improvements in liver inflammation, steatosis and fibrosis-related outcomes in adults with metabolic dysfunction–associated steatohepatitis (MASH) and liver scarring. Notably, a mediation analysis suggests these liver benefits are not explained solely by the magnitude of weight loss, implying potential weight-independent effects of semaglutide on liver health. [1][2] Key findings Semaglutide 2.4 mg recipients experienced greater improvement in liver injury (steatohepatitis) and liver-related non-invasive tests c...

Wegovy® (Semaglutide) Receives Health Canada Approval for MASH Treatment Breaking: Health Canada Authorizes Wegovy® as First Treatment for Non-Cirrhotic MASH In a landmark decision for liver health, Health Canada has granted Notice of Compliance with Conditions (NOC/c) for Wegovy® (semaglutide injection) . This authorization makes it the first and only treatment available in Canada specifically for adults with non-cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) who have moderate to advanced liver fibrosis. This approval marks a significant turning point in the management of liver disease, offering a targeted pharmaceutical option for a condition that previously relied heavily on lifestyle management alone. Key Takeaways First Mover: Wegovy® is the first approved treatment in Canada for MASH. Target Patient: Adults with non-cirrhotic MASH and stage F2 or F3 fibrosis. Clin...

Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...

Novo Nordisk has stood up on the side of Victoza after persuasive US buyer bunch Public Resident required the diabetes medication to be removed. Public Resident has asked the US Food and Medication Organization to quickly eliminate Victoza (liraglutide) from the market "since it puts patients at higher gamble of thyroid disease, pancreatitis, serious hypersensitive responses and kidney disappointment that offset any recorded clinical advantage". The backing bunch guarantees that the once-everyday human glucagon-like peptide-1 (GLP-1) simple "is the main medication endorsed by the FDA or in the endorsement pipeline that causes thyroid C-cell growths in the two genders of rodents and mice, doing as such at drug openings like those found in individuals taking the suggested portion - a striking admonition sign". Additionally, in the initial 17 months of Victoza being available, 200 patients were determined to have intense pancreatitis, as per Public Resident's audit...

Emcure Launches Poviztra: A New Era for Weight Loss in India Emcure Launches Poviztra: Revolutionizing Weight Management in India Published: December 22, 2025 | Pharmaceutical News India In a major milestone for Indian healthcare, Emcure Pharmaceuticals has announced the commercial launch of Poviztra® (Semaglutide). As the first Indian company to exclusively commercialize this blockbuster molecule from Novo Nordisk, Emcure is set to transform the landscape of obesity treatment in the country. The Breakthrough: Poviztra is a once-weekly semaglutide injection specifically indicated for chronic weight management. It offers the same efficacy as global brands but is tailored for the Indian market through Emcure’s extensive reach. Affordable Access to Global Innovation One of the most significant aspects of this launch is the pricing strategy. Emcure has positioned Poviztra as a highly competitive op...

Weight Loss Drugs and the Indian Pharmaceutical Economy: A New Era of Health and Business 💊 The New Revolution in Weight Loss: Beyond Diets and Gyms Weight management is no longer limited to gym routines and calorie counting. India’s healthcare landscape is witnessing a scientific revolution driven by advanced weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) . These modern therapies are reshaping the country’s pharmaceutical economy, creating new business opportunities for both global and Indian companies. 🇮🇳 India’s Weight Loss Drug Boom in 2025 According to Reuters , India’s weight loss drug market crossed ₹600 crore in mid-2025 — a growth rate few other pharma categories can match. Global giants like Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are driving the wave, while Indian companies such as Dr. Reddy’s, Lupin, Zydus, and Sun Pharma are fast-tracking their own anti-obesity formulations. For perspective, Mounjaro was launched ...

Breaking: EMA's CHMP Backs High-Dose Wegovy® (7.2 mg) for Obesity Treatment Breaking: CHMP Recommends Approval of High-Dose Wegovy® (7.2 mg) for Obesity The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of a new, higher dose of Wegovy® (semaglutide 7.2 mg) . This major regulatory milestone brings a more potent option to patients in the European Union, offering the potential for significantly greater weight loss compared to the standard 2.4 mg maintenance dose. Key Takeaways New Dose Strength: 7.2 mg once weekly (previously capped at 2.4 mg). Efficacy: Clinical trials demonstrated an average weight loss of 20.7% . Target Audience: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. Next Step: Final approval from the European Commission is ...